Abbvie Sustainability

2019
Responsible
Action
Report
Table of contents
A message from our CEO . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Our company and our business. . . . . . . . . . . . . . . . . . . . . 2
2019 highlights. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Our approach to corporate responsibility. . . . . . . . . . . . 4
Making a remarkable impact for patients. . . . . . . . . . . . 7
Building and supporting a diverse, . . . . . . . . . . . . . . . . . 19

high-performing workforce
Making positive contributions to society. . . . . . . . . . . . 27
Looking ahead. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
The purpose of this report is to describe our approach to corporate

responsibility and our recent work to advance our responsibility priorities.
2019 Responsible Action Report 1
A message
from our CEO
At AbbVie, we are guided in everything we do by our desire to make a remarkable impact
on the lives of patients.
As we launched new treatments in immunology and oncology and continued to advance

our pipeline, we also worked collaboratively with many external partners to advance
long-term efforts in eliminating hepatitis C, treatments for neglected tropical diseases,
evidence-based disease management, health care access and community resilience. “Making a remarkable
The decision to acquire Allergan is part of our strategy to ensure long-term sustainability impact requires
for AbbVie and increase our ability to meet the needs of patients. Allergan brings taking the long
therapeutic area leadership, diversification and resources that will help fuel continued view – of investment,
investment in research on new treatments for debilitating and life-threatening conditions
research and
such as cancer and neurodegenerative disease.
development and
The COVID-19 pandemic that emerged at the end of 2019 has challenged governments,
how we can be an
health care providers and researchers around the world to act quickly in an effort to save
lives. Like many of our peers, AbbVie has responded rapidly to requests from countries
effective long-term
and organizations around the world for medicine, clinical research and financial support. partner in health
We also recognize that the pandemic is far from over and we will continue to do our and well-being.”
part to protect and support our patients, employees and stakeholders in this changing
environment.
It is my pleasure to introduce the AbbVie 2019 Responsible Action Report. It is intended

to share some of the many ways we run a successful business that makes a genuine and
lasting impact for patients, employees and communities.
Sincerely,
Rick Gonzalez
Chairman & CEO
2 2019 Responsible Action Report
Our company and our business 2019
30,000+
AbbVie is a global, research-based biopharmaceutical company
committed to discovering, developing and delivering innovative
medicines with distinct and meaningful benefits for people. We
aim for transformative change, not just incremental improvement. Employees
Our medicines help people living in more than 175 countries and
help treat patients with conditions such as chronic autoimmune
diseases, cancer, virologic diseases, neurological disorders,
metabolic diseases and other serious health conditions.
70+
Countries with employees
Our state-of-the-art research, development and manufacturing
centers across the world allow us to perform cutting-edge
research and to move the best ideas forward faster. In addition
to our North Chicago headquarters, we have discovery and
8
Research & development centers
development centers in the Boston, Massachusetts area and the
14
San Francisco Bay Area, California, United States; Ludwigshafen,
Germany; and Tokyo, Japan. We have manufacturing facilities
in the United States, Puerto Rico, Italy, Ireland, Germany and
Singapore, and our supply chain spans more than 120 countries Manufacturing facilities
and all 50 U.S. states.
The acquisition of Allergan will provide AbbVie with leading
marketed products, both expanding and diversifying our
business and aligning with our gastroenterology and
175+
Countries where our products are sold
neuroscience focus areas.
We are a passionate, diverse and inclusive organization with
a culture that supports the best ideas, wherever they originate.
Bringing diversity of thought to the collaborative process helps
52M+
Patients treated globally
us break barriers and explore new frontiers in science.
2019 Highlights
Research and development
We achieved nine new product approvals or indication expansions from major regulatory authorities. These
included approval of new treatments for rheumatoid arthritis and moderate-to-severe plaque psoriasis, as
well as new treatments for previously untreated chronic lymphocytic leukemia.
Access to medicine
We expanded our U.S. patient assistance program, myAbbVie Assist, providing free AbbVie medicines to more
than 89,000 qualified patients.
Equality, diversity and inclusion

We implemented a new five-year global Equality, Diversity and Inclusion strategy, with goals linked to executive
compensation and an inclusive leadership toolkit for people managers. We also launched a seventh Employee
Resource Group, Ability at AbbVie, to address the needs and concerns of people with disabilities and their
caregivers.
Environmental sustainability
We launched a new environmental sustainability strategy focused on reducing our environmental footprint,
ensuring sustainable growth as well as inspiring, educating and engaging our workforce to steward
sustainability within and beyond AbbVie.
Employee volunteerism and community engagement

AbbVie employees around the world volunteered more than 68,000 hours in their communities and dedicated
another 20,000 hours conducting pro bono research and development projects.
We are proud of recognition received and use it to benchmark our efforts.

Dow Jones Sustainability AbbVie was again named to the Dow Jones Sustainability World Index, as we have every year
World Index since our founding in 2013.
FTSE4Good Index AbbVie has been a constituent of the FTSE4Good Index since 2016.
CR Magazine’s 100 Best In 2019, AbbVie made its first appearance on the list, ranking in the top 20 for outstanding
Corporate Citizens environmental, social and governance transparency and performance among the 1,000 largest
U.S. public companies.
The Civic 50 For the sixth year, AbbVie was recognized as one of America’s most community-minded
companies and honored by The Civic 50 for our commitment to improving quality of life in
communities where we do business.
PEOPLE’s Companies AbbVie was one of PEOPLE’s 50 U.S. companies highlighted for caring for their communities, their
that Care employees and the world.
World’s Best Workplaces For the third year in a row, AbbVie was on the World’s Best Workplaces list from Fortune and Great
Place to Work.
DiversityInc Top 50 AbbVie was again named to the DiversityInc Top 50 Companies for Diversity in the United States,
Companies for Diversity as we have every year since 2014.
Working Mother’s For the second consecutive year, AbbVie was among the Top 10 companies on Working Mother’s
100 Best Companies 100 Best Companies list, in our seventh year on the list.
Our approach to corporate

responsibility
At AbbVie, we strive to make a remarkable impact on
patients and drive sustainable growth by discovering and
delivering a consistent stream of innovative medicines
Materiality
that address serious health problems. Our corporate responsibility priorities reflect the most
Our Principles articulate what we believe to be right and true. material drivers of our success, as well as the issues
They are foundational to our culture and guide our priorities, that are of greatest significance to our employees and
decisions and behaviors: stakeholders, including health care providers, investors,
non-profit partners, patients and patient organizations,
• Transforming Lives
payers, policymakers and suppliers.
• Acting with Integrity
Through regular and routine engagement with internal and
• Driving Innovation
external stakeholders, those drivers have been identified as:
• Embracing Diversity & Inclusion
• Product innovation and R&D productivity
• Serving the Community
• Drug pricing, reimbursement, intellectual property and
These are long-term ambitions, supported by many day-to-day biosimilar landscape
actions. We consider it our responsibility to ensure that the • Product quality and security
actions we take every day align with our principles and support
• Transparency, ethics and compliance
our goals, being thoughtful about how our business decisions
affect the many stakeholders we impact. • Health and well-being at all ages
• Environmental stewardship
The AbbVie Board of Directors and its Public Policy Committee
oversee our corporate responsibility strategy. We also evaluate our efforts relative to external frameworks
such as the Dow Jones Sustainability Index, CDP and
the Sustainability Accounting Standards Board (SASB).
Through this process, we have identified additional topics
of importance to AbbVie and our stakeholders, including:
• Equality, diversity and inclusion
• Talent attraction, retention and development
• Community engagement
Our corporate responsibility framework

Our Corporate Responsibility framework shows how our mission, our corporate strategy and our materiality assessment come
together in clear priorities that guide our actions.
We strive to make a remarkable impact on patients and drive sustainable

Corporate
strategy
growth by discovering and delivering a consistent stream of innovative
medicines that address serious health problems.
Driving innovation Acting with integrity Serving the community
Principles Transforming lives

Embracing diversity and inclusion
Creating real health improvement We recognize that health is of The health of our business
is our mission and the premise fundamental importance to all is intertwined with that of our
of our business. To be a leading people. To participate over the communities. We can use
health care innovator, we must long term in the provision of our unique resources to
attract, retain and support a health care, we must earn and support well-being, resilience
diverse workforce and invest in maintain the trust of patients, and growth in the communities
efforts to develop medicines health care providers, regulators, where we do business and help
that bring value for patients. policymakers and the public. lay the foundation for broader
community vitality.
Corporate
Use our expertise Steward our ethical and Support long-term
responsibility
priorities to improve health sustainable business community strength
Key issues We conduct research to make We advance patient, family and

impacting: We maintain high standards
innovative medicines that offer caregiver well-being through
of ethics, safety and quality.
Patients real patient benefit. education and support.
We promote a diverse, inclusive

We protect human rights and We support our people so they
Employees workplace and invest in
workplace safety. can be their best every day.
development to drive innovation.
We support communities through

We give medicines, expertise and We prioritize environmental
economic activity, employee
Society funding to promote health needs sustainability across our business
community engagement
of the underserved. and supply chain.
and philanthropy.
Our contributions to the Sustainable Development Goals

The United Nations developed the 2030 Agenda for Sustainable Development, a blueprint for achieving the vision of a better and
more sustainable future for all. Underpinning the agenda are 17 Sustainable Development Goals (SDGs), each with multiple sub-
targets. At AbbVie, we want to contribute to the achievement of the Agenda by advancing the goals and sub-targets that align most
closely with our capabilities and responsibility commitments. We’ve identified six SDGs and, within them, key sub-targets as our
primary focus. Our activities may also advance other goals and we continuously evaluate opportunities to expand our contributions.
Learn more about the SDGs here.
SDG Relevant Sub-Targets AbbVie’s Role

3.2 End preventable deaths of newborns and children < 5 years Our research on neglected tropical diseases, tuberculosis and
of age malaria will help to directly address these targets.
3.3 End AIDS, tuberculosis, malaria and neglected tropical Our medicines treat respiratory conditions in premature newborns,
diseases; combat hepatitis, water-borne diseases and other HIV, hepatitis C and cancer.
communicable diseases
3.4 Reduce premature mortality from non-communicable diseases
through prevention and treatment; promote mental health and
well-being
4.1 Ensure all girls and boys complete free, equitable, quality Education enables the achievement of other goals, including health
education and prosperity.
4.4 Increase the number of people who have relevant skills for Supporting effective educational programs for school-age children
employment, decent jobs and entrepreneurship is a philanthropic priority for AbbVie and the AbbVie Foundation.
4.5 Eliminate gender disparities in education and ensure equal By engaging our highly educated workforce, we advance skill
access to education and training for the vulnerable development for underserved students through mentorship, training
4.A Build and upgrade education facilities that are child, disability and exposure to STEM projects.
and gender sensitive and provide safe, nonviolent, inclusive
and effective learning environments for all
5.1 End all forms of discrimination against all women and girls At AbbVie, we respect the human rights of all individuals. We
5.2 Eliminate all forms of violence against women and girls in the appreciate the contributions that women – and people of all
public and private spheres, including trafficking and sexual and backgrounds – make to an enterprise where diversity of thought
other types of exploitation drives innovation.
5.5 Ensure women’s full and effective participation and equal Our anti-discrimination, anti-harassment and anti-violence policies
opportunities for leadership at all levels of decision-making extend through our organization and to our suppliers. We pursue
in political, economic and public life equality through deliberate action in our company, with our suppliers
and in our communities.
8.1 Sustain per capita economic growth in accordance with We have employees around the globe and purchase goods and
national circumstances services from a supplier network spanning over 120 countries and
8.2 Achieve higher levels of economic productivity through all 50 U.S. states.
diversification, technological upgrading and innovation We prioritize recruiting and hiring from historically underrepresented
8.5 Achieve full and productive employment and decent work for groups and provide economic opportunity and technical support to
all women and men, including for young people and persons small and diverse suppliers.
with disabilities, and equal pay for work of equal value Supporting communities is also a priority of the AbbVie Foundation.
We partner with nonprofit organizations and engage our employees
to provide learning and workforce readiness programs.
12.2 Achieve sustainable management and efficient use of We have set absolute targets for reduction of our carbon emissions,
natural resources water consumption and waste generation and are actively taking
12.4 Achieve environmentally sound management of chemicals steps to meet them.
and wastes; significantly reduce their release to air, water and Through participation in CDP, we are transparent in reporting our
soil to minimize adverse impacts on health and the environment environmental impacts.
12.5 Reduce waste generation through prevention, reduction,
recycling and reuse
12.6 Encourage companies to adopt sustainable practices and
integrate sustainability information into their reporting cycle
13.1 Strengthen resilience and adaptive capacity to As a provider of medicines that patients rely on, we anticipate
climate-related hazards and natural disasters in and mitigate climate-related risks that could impact our continuity
all countries of supply.
We also support disaster relief partners to help to strengthen
community resilience and recovery from climate-related hazards.
Making a remarkable impact

for patients
Patients are the reason we come to work every day. They are at the heart of
our guiding Principle of transforming lives.
In this section:
Science and innovation are the cornerstones of our business. We focus on We invest in research to make
discovering, developing and delivering medicines for challenging diseases innovative medicines that offer real
where we have expertise and can make a real impact for patients. patient benefit
To do this, we must ensure that we deliver medicines reliably, with quality and
safety patients can trust. We must act with integrity to maintain that trust. We maintain high standards of ethics,
safety and quality
We also understand that making a remarkable impact for patients takes more
than medicine. That’s why we provide broader patient and family support, We advance patient, family and
contribute research and funding to public health initiatives and support
caregiver well-being through
independent medical education.
education and support
Commitment: Use our expertise to improve health
We invest in research to make innovative medicines

that offer real patient benefit.
Building new understanding and finding genuinely novel We know that the true value of a medicine is in the difference
solutions is critical to our mission. Our vision is to help create it makes in a patient’s everyday life. We are investing in new
transformative change, not just incremental improvement. For ways to bring a patient focus into the lab and the clinic as we
autoimmune diseases, that means aiming for remission, not just develop innovative treatments. This means using patient input
the management of symptoms. For cancer, it means finding ways to understand what outcomes really matter and pioneering new
for patients to achieve better and longer-lasting treatment results. methods to measure them in accurate and relevant ways.
In neuroscience, it means continuing to pursue ways to slow,
We understand that our research, expertise and medicines can
halt and ultimately reverse the damage of debilitating conditions
make a real impact on public health and disease management.
such as Parkinson’s and Alzheimer’s diseases.
We continue to conduct research to help improve screening,
Developing innovative medicines requires extensive investment diagnosis and disease management in our therapeutic areas
in the high-risk process of research and development. Our of focus.
Development Design Center is a Center of Excellence that
We maintain a pro bono research program where AbbVie
integrates tailored expertise, predictive analytics and machine
researchers and development experts donate paid work time
learning to deliver innovative, efficient and quality clinical trial
to collaborations with global health partners to address unmet
approaches aimed at broadening study populations, accelerating
needs and public health issues, particularly those affecting
recruitment, reducing cost and improving the patient experience.
people in low- and middle-income countries. We also offer our
expertise to help build health system capabilities where they
are needed.
Our progress
We invested $5 billion in research and development in Investing in novel solutions also requires us to be
2019, continuing to focus on areas of very high need and courageous in the face of tough decisions and to learn
potential impact: from setbacks that are inevitable in the scientific process.
In 2019, we discontinued clinical development for some of
$5B in R&D our antibody-drug conjugates, most notably Rova-T and

ABT-414, but have taken from this research key learnings
that have helped to refocus our efforts on other proprietary
antibody-drug conjugates.
Beyond moving compounds through the pipeline, we also
helped to advance development science. Throughout 2019,
our teams worked closely with the FDA and other regulatory
agencies to define and realize the opportunities real-world
Immunology Neuroscience Oncology evidence (RWE) offers for better medical care. AbbVie is also
actively involved in a public-private research partnership with the
We achieved nine new product approvals or indication Duke-Margolis Center for Health Policy, which published multiple
expansions from major regulatory agencies during the year. papers exploring practical aspects of using real-world data in
These included approval of new treatments for rheumatoid regulatory decision-making during the past year.
arthritis and moderate-to-severe plaque psoriasis as well as
new treatments for previously untreated chronic lymphocytic
leukemia. Many of our late-stage candidates have been granted
regulatory designations to expedite development or review,
with recognition of their potential to address unmet needs.
Four additional programs received such designations in 2019.
In 2019, we expanded our early-stage research portfolio
through internal discovery, new and expanded research
collaborations and smaller acquisitions. With the acquisition – Mohit Trikha, Ph.D.,
of Mavupharma, an expanded collaboration with Harpoon Vice President and
Therapeutics, a strategic collaboration with Tizona and a Head of Oncology Early
licensing agreement with Teneobio, we enhanced our portfolio Development, AbbVie
of immuno-oncology platforms and clinical-stage assets. We also
broadened our research collaboration with Scripps Research to "The best way to develop transformational
include projects in oncology, immunology, neurology and fibrosis. medicines is through collaborations that
Three significant research collaborations achieved key bring together the brightest minds. This
milestones in 2019. ABBV-4083, an investigational compound
that AbbVie is co-developing with Drugs for Neglected Diseases partnership with Scripps Research will
initiative (DNDi), had a successful End of Phase 1 meeting with collaboratively advance next-generation
the FDA. The project is a part of our pro bono research program,
where more than 330 researchers and development experts
programs, build stronger relationships with
contributed over 20,000 hours in 2019. A Phase 2 study in proven and emerging scientific leaders
patients with river blindness will be conducted by DNDi with and, most importantly, help us advance
drug product and pro bono technical support from AbbVie.
novel medicines for patients.”
Our collaboration with Calico, the Alphabet-backed life sciences
company focused on aging-related research and therapeutics,
saw the identification of the first two clinical candidates from the
partnership. These compounds – one in oncology and one in
neuroscience – will enter clinical trials in 2020.
We also announced the identification of the first several
potential drug targets in our research collaboration with Mission
Therapeutics on neurodegenerative diseases. In recognition of
its significance and impact, the collaboration between Mission
and AbbVie was shortlisted for Scrip’s 2019 Best Partnership
Alliance Award.
Working closely with regulators, we piloted the use of AbbVie researchers made important contributions to the
observational data and machine learning to improve the effort to eliminate hepatitis C (HCV). The World Health
efficiency of drug development. For example, using advanced Organization (WHO) has set a target to eliminate HCV by 2030,
analysis methods to characterize existing data, our researchers and AbbVie is committed to supporting that vision. Developing
were able to reduce the size of control groups for two clinical an effective strategy to eliminate a disease means knowing
studies by half, supplemented by information already learned where affected patients are located and understanding the
about control performance. characteristics of those populations. AbbVie is using digital
innovation to create the most comprehensive epidemiology
We continued to advance our efforts to measure the
resource available to those involved in developing and executing
practical treatment outcomes that matter most in patients’
local strategies to eliminate HCV in the United States. We have
everyday lives. Drug development often relies on data collected
integrated screening laboratory data from two large laboratory
at pre-determined intervals using site-visit observations and
companies and applied machine learning techniques to fill
retrospective patient surveys. The challenge is that not all relevant
gaps in the data. The result is a resource that states can use to
patient outcomes can be effectively measured using these
evaluate progress toward elimination and adapt their strategies
techniques. To address these challenges, we have been building
accordingly.
our knowledge and experience with the use of wearable digital
tools to collect data from patients, both in the controlled trial In 2019, we also formalized a collaboration with the Coalition
setting and in the real-world setting. These tools provide objective for Global Hepatitis Elimination to support the development of
measurement and remove the error associated with methods that tools and resources to track and advance progress toward HCV
rely on patient recall. elimination around the world. AbbVie is supporting this work by
providing key data insights, analyses and expertise around HCV
burden and the path to elimination. View the Coalition’s work here.
Health outcomes research collaborations advancing patient care

Some real-world questions about the patient experience, such as optimal sequencing of newer
treatments, cannot be answered through a regular clinical trial. AbbVie has partnered with Memorial
Sloan Kettering Hospital and 25 investigators from leading institutions around the world on the Chronic
Lymphocytic Leukemia (CLL) Collaborative Study of Real-World Evidence (CORE). It represents the
largest cohort data to date on treatment sequencing in CLL.
AbbVie is a partner in the HARMONY Alliance, a public-private network designed to gather and analyze
big data to uncover opportunities to speed the development of new treatments and more effective
treatment strategies for patients with blood cancers. In 2019, the Alliance hit a key milestone, identifying
data records for over 45,000 patients across Europe with blood cancer, hosted on a data platform that’s
one of the largest of its kind in the world.
Because we know that achieving lasting health impact takes Outside the U.S., our AbbVie Care program includes a wide
more than medicine, we continued to provide broad patient range of disease- and country-specific patient programs that
support, to enable the best possible health outcomes. provide meaningful, informative and empowering support to
In the U.S., our support programs help patients more fully patients who have been prescribed AbbVie medicines. These
understand their disease and the treatment they have been programs are tailored to the needs and regulations in each
prescribed. Through these programs, we offer one-to-one country and patient community.
education and support through personalized interactions,
AbbVie personnel do not give medical advice and are trained
help patients adjust to the use of their medicine and, in some
to direct patients to their health care professional for any
programs, provide lifestyle management support to further
treatment-related questions.
promote health.
Key performance indicators
Investment and Innovation 2016 2017 2018 2019
Research and development investment (adjusted) $4.15B $4.83B $5.09B $4.98B
New product or indication approvals including indication expansions 9 7 9 9
Number of programs granted a designation by at least one major regulatory 5 9 5 4

authority to expedite development or review
Percent of compounds in clinical development with a novel mechanism of action 67% 67% 72% 72%
Research hours donated to neglected tropical diseases, malaria and tuberculosis 21,583 30,006 39,945 20,621
Commitment: Steward our ethical and sustainable business
We maintain high standards of ethics, safety

and quality.
Ethics Research is foundational to our work. To have a lasting positive
impact, we must conduct our research ethically, beginning in
In order to make a positive long-term impact for patients, we the lab and extending to the clinic.
must earn and maintain their trust by acting with integrity in
everything we do. Through our Code of Business Conduct While animal testing is required by law for the development
and our Supplier Code of Conduct, we set clear expectations of new medicines, we consistently apply the internationally
for appropriate behavior. accepted “3Rs” principles. This means that we seek to reduce
the number of animals required to achieve research objectives
Our Code of Business Conduct when possible; replace animal studies with non-animal or
sentient alternatives; and if animals must be studied, refine
applies to all employees globally our practices to minimize any potential for pain and/or distress.
Our Commitment to Humane Care and Use of Animals outlines
and is available in 31 languages. our approach.
Each year, all employees are Safety
required to complete training on Every year, tens of thousands of patients worldwide participate in
the Code and certify that they will clinical trials of potential AbbVie medicines. It’s because of these
clinical trial participants that we can eventually bring medicines
adhere to it. to many more patients. Their safety is our first priority.
We require all AbbVie clinical studies to be conducted in a
We support our employees in upholding these expectations
manner consistent with the ethical principles outlined in the
through additional policies and procedures, a robust training
World Medical Association’s Declaration of Helsinki, and
program, monitoring and auditing and a well-publicized
to adhere to applicable standards set by the International
disclosure program.
Council for Harmonisation of Technical Requirements for
Our policies and procedures are designed to help ensure Pharmaceuticals for Human Use. This includes adherence to
adherence to relevant laws and industry codes, including the Good Clinical Practice, Good Laboratory Practice and Good
U.S. Anti-Kickback Statute, U.S. Foreign Corrupt Practices Manufacturing Practice standards.
Act, U.S. Physician Payments Sunshine Act, General Data
Once our medicines are approved and marketed, we maintain
Protection Regulation, EFPIA Code on Disclosure to Healthcare
a robust pharmacovigilance program. Our safety team of
Professionals and Healthcare Organizations, IFPMA Code and
physicians and scientists are recognized experts both within
PhRMA Code on Interactions with Health Care Professionals.
and beyond the company, actively advancing the field in Our global operations are subject to a wide range of risks that
collaboration with academic scientists, health authorities and have potential to impact the continuity of our business, the supply
industry peers. Our integrated, multi-disciplinary approach and of medicine for the patients who rely on them and our employees.
advanced technology are designed to identify potential safety Within Global Security, our Crisis Management function
signals early and minimize risk. We routinely achieve over 98 works across the enterprise to help ensure preparedness for
percent on-time expedited reporting of adverse events to FDA and resilience to these risks. These risks include, but are not
and the European Medicines Agency (EMA). limited to, natural disasters, cyberattacks, security breaches
and product-related issues such as supply chain interruptions,
Quality counterfeiting and diversion.
We have robust systems in place to ensure the medicines Counterfeiting and diversion of medicines pose risks to patient
we manufacture are high quality and available when patients health and safety. Our Global Anti-Counterfeiting Steering
need them. Our Quality Council oversees our quality strategy Committee is responsible for identifying and mitigating these
and is accountable directly to our CEO. Highly skilled and risks related to AbbVie medicines. They coordinate proactive
experienced teams oversee every aspect of our manufacturing strategies for preventing counterfeiting and diversion of our
processes, from the suppliers who provide the inputs to the medicines and conduct routine monitoring to identify signals of
product delivered. possible counterfeiting or diversion. Our measures include visible
We use an integrated enterprise quality management system and invisible product features to verify authenticity, multiple and
that complies with applicable standards from the International overlapping product tracking methods from origin to destination
Organization for Standardization (ISO), the International and close partnership with local law enforcement authorities
Council for Harmonisation of Technical Requirements for around the world.
Pharmaceuticals for Human Use and regulatory authorities. We also take strong proactive measures to maintain the security
We use both internal and external audits to ensure ongoing of our supply chain. A secure supply chain helps to ensure not
product quality. only quality but also a faster and more efficient process to reach
Though we produce many of the most critical components of customers and patients. To ensure the security of our materials
our products in-house, we also purchase inputs from thousands as they move across borders, we participate in the Trusted Trader
of suppliers across the globe. From among these, we identify programs run by the U.S., E.U. and other customs authorities.
our most critical suppliers. This classification is based on many Through these programs, U.S. Customs and Border Protection,
criteria, but the potential impact of a supplier issue on product E.U. customs authorities, as well as additional countries’ customs
efficacy, safety, availability or patient experience is paramount. authorities inspect and certify our security measures. The
For our most critical suppliers, we require strong controls and primary sources for AbbVie of finished commercial products are
close involvement of AbbVie experts, including regular in-person received by locations in Trusted Trader programs.
and remote audits. Further, we continuously monitor the evolving
legal and regulatory landscape to ensure that the chemicals,
mixtures and commodities in our products, including purchased
inputs, are compliant with applicable regulations.
Our progress
Ethics The Global Animal Welfare and Comparative Medicine

programs implemented a new training program in 2019
Our commitment to ethics and integrity remained a to further enhance the efficiency and effectiveness of
focus of sustained efforts. To complement our Principle our staff. These training improvements have enabled broader
of acting with integrity, we launched a Leading with Integrity support for our animal programs. We continued to welcome
communications campaign. People who manage others set employee volunteers in our canine enrichment program.
the day-to-day expectations for our employees and provide the Volunteers provide socialization, outdoor exercise, enrichment
most visible example of our culture. The campaign reinforced and pre-adoption acclimation for our research animals.
our fundamental belief that a culture of integrity is essential to
strong business performance because it supports high levels Two of our research sites underwent re-accreditation with
of quality, compliance and safety, builds trust and underpins AAALAC International, a private, nonprofit organization that
strong partnerships. promotes the humane treatment of animals in science through
voluntary accreditation and assessment programs. As a result
In 2019, as in past years, all employees received AbbVie’s of this process, both our Massachusetts- and Illinois-based sites
annual training on our Code of Business Conduct, and were granted “exemplary status” by this respected third party.
employees in relevant functions received mandatory training Exemplary status is shared by only 2 percent of the AAALAC
on topics such as anti-corruption and anti-bribery, conflicts accredited units worldwide.
of interest, recognizing and reporting safety information,
appropriate product promotion and appropriate interactions Our research teams continued to advance the 3Rs (reduce,
with health care providers and patient groups. Our compliance replace, refine) for ethical treatment of animals. Through our
training is continually reviewed and updated as the environment 3Rs Impact Award Program, scientists who adopt and implement
and our business evolves to ensure employees are receiving the the 3Rs are acknowledged for their efforts. In 2019, 40 research
most relevant and timely information on these important topics. teams were recognized for using advanced technologies,
improved modeling and in vitro platforms to reduce the number
In recognition of our transparency regarding political activities of animals required and, where appropriate, replacing animal use.
and donations, in 2019 we were again named to the Center for
Political Accountability’s list of “trendsetters” — the highest
scoring tier — in their annual CPA-Zicklin Index of Corporate
Political Disclosure and Accountability.
Safety We continued to advance the knowledge, skills and

effectiveness of our safety teams, from those working
Our Pharmacovigilance and Patient Safety teams advanced on the drug development process to those interacting
a key initiative to use large observational data sets to with patients. For example, drug-induced liver injury (DILI)
advance our post-marketing safety capabilities. By gathering remains an issue of concern for patients and providers and the
and integrating large sets of observational data in the therapeutic pharmaceutical industry. In 2019, our internal safety advisory
areas and patient populations where our medicines are used, groups hosted an educational forum for approximately 300
we are proactively building contextual knowledge to help us AbbVie R&D employees, led by four world-renowned expert
rapidly evaluate adverse event reports, respond to stakeholder hepatologists. The discussion focused on prediction, prevention
questions quickly with high quality evidence and support and management of DILI and will help our teams collect the
improved decision-making for the health and safety of patients. right data at the right intervals to better recognize DILI as a
We launched AbbVie’s first machine learning robot designed safety signal.
for use in a regulated setting. Nicknamed “Q,” this virtual digital We are also using learnings and tools from behavioral
worker represents a significant advancement in our ongoing science to enhance the ways we teach patients to use
efforts to use automation to increase efficiency. The development our medicines, with the goal of reducing medication
and training of “bots” like Q is part of our strategy to proactively errors and improving adherence. This year, we began to
build internal knowledge and capabilities in this emerging space. systematically incorporate the use of teach-back, an established
As technical validation standards emerge over the coming years, health literacy technique, into our interactions with patients
we aim to be prepared to engage productively with regulators using our injectable medicines. Teach-back helps us to better
and to help advance the use of these techniques across the understand how patients interpret the information we give them,
industry, for the benefit of patients. which in turn allows us to further adapt our communications to
address patient needs.
Drawing on insights from data science, patient
safety and human behavior, Q was developed
through a collaboration between our safety
team, our business technology team and
students at the AbbVie Innovation Center at
the University of Illinois Urbana-Champaign.
Quality
To ensure quality and regulatory compliance, AbbVie Our goal is to have no backordered medicines, as
manufacturing sites received dozens of external inspections backorders can cause treatment interruptions and impact
and audits. Most were from major regulatory health authorities patient outcomes. We maintained a consistent supply to meet
such as the U.S. FDA, the European Medicines Agency and the demand at nearly all times. In 2019, backorders comprised fewer
Japanese Pharmaceuticals and Medical Devices Agency. None than 0.01 percent of the total orders we filled. Our assurance of
of these audits had findings resulting in production stoppages. supply program is designed to help us maintain supply even in
unpredictable circumstances, such as natural disasters or surges
We conducted our own quality assessments and audits of
in demand. We identify and qualify backup suppliers, scan the
our most critical suppliers to ensure they are upholding
environment for potential risks and plan for alternate scenarios.
our quality standards. The frequency and method of supplier
quality assessment is based on a detailed risk evaluation as In 2019, we implemented serialization of our medicines
specified in our supplier quality policies and procedures. In in Europe, in accordance with the E.U. Falsified Medicines
2019, we conducted in-depth quality assessments of 491 Directive. We also optimized our global supply chain security
supplier sites. We remained focused on those sites with the and product protection system, which will allow us to
greatest potential to impact product efficacy and safety, aiming continuously adapt to an increasingly complex supply
to assess each of these in-depth at least once every three chain landscape.
years. In the three-year period ending December 31, 2019, we
We expanded internal and external training on
conducted detailed assessments of more than 95 percent of
counterfeiting- and diversion-related risks and protocols.
these sites at least once—some more frequently—with the
More than 380 AbbVie employees were educated and trained
majority of these assessments taking place in-person.
on topics such as the social and health risks of counterfeiting
and diversion, common illicit trade practices and security
protocols. We also trained more than 1,600 health care providers
and law enforcement officials in higher-risk geographies on
challenges and impacts associated with diverted and/or
counterfeit medicines.
Ethics, Compliance, Safety and Quality 2016 2017 2018 2019
Number of employees certifying on the AbbVie Code of Business Conduct* 28,580 28,906 29,595 29,160
Number of regulatory inspections of AbbVie commercial manufacturing facilities 41 52 37 27
Rate of expedited adverse event reporting to EMA >98% >98% >98% >98%
Backorders as percentage of total orders <0.01% <0.01% <0.01% <0.01%
Number of supplier sites assessed in-depth for quality 488 540 474 491
Percentage of supplier sites with greatest impact on product quality and safety 32% 41% 41% 48%
assessed in-depth†
* This figure fluctuates with the workforce.

†
Some sites not assessed during the four-year period are new and still within the required audit window.
Commitment: Support long-term community strength
We advance patient, family and caregiver well-being

through education and support.
Patients look to their families, caregivers and communities to play • Additionally, the U.S. Immunology Scholarship aims to
a pivotal role during their health journey. We want to help ensure empower exceptional students living with inflammatory
they can receive broad care and support when it’s needed most. diseases to pursue an independent life through their
unyielding determination. Since its inception in 2016, the
We support educational programs that equip patients with the
program has awarded more than 100 scholarships to students
knowledge and resources to understand their diseases. These
living with immune-mediated conditions.
programs help make connections with patient organizations,
patient support activities, online programs and educational Science and medicine are constantly changing. Patients trust
materials where they can learn more about their diseases and that their health care team is equipped with the latest information
how to engage with other patients. and resources to make the best choices for their treatment and
help them navigate through it. AbbVie’s support of independent
Each patient has a unique journey. The nonprofit organizations
scientific and medical education programs offers unbiased
we support provide patients, loved ones and caregivers with
continuing education for experienced health care providers and
necessary information and tools to manage their diseases.
scientists on current, new and emerging science.
These resources empower them to be active participants in
their health journeys. Some of the nonprofit organizations We also provide funding for fellowships that allow health care
providing impactful programming include the National providers who are new to their fields to continue their training
Parkinson’s Foundation, Arthritis Foundation, PACKHealth, and increase their experience and knowledge in their specialties
Leukemia Research Foundation and CancerCare. of interest. Our hope is to close the gap in under-resourced fields
by providing opportunities for the next generation of providers.
We understand that the health care conditions we treat don’t
define the patients we serve. AbbVie offers scholarships to help
patients reach their educational goals:
• AbbVie’s Cystic Fibrosis Scholarships provide financial
support to young adults with cystic fibrosis as they pursue
undergraduate and graduate degrees in the United States.
The program has awarded over $3.3 million in scholarships
in its history of more than 25 years.
Our progress
In 2019, we continued our support for unique and innovative • Education in the hepatitis C community that breaks down
educational programs for both patients and providers. barriers and moves the world closer toward elimination
We reached more than 415,000 patients through independent • An initiative involving cancer patients, caregivers and health
patient education grants and more than 580,000 health care care providers working together to determine a customized
providers through independent medical education grants. Some treatment plan
examples of programs we supported include:
Additionally, AbbVie was proud of the progress our partners
• A program to encourage young physicians to explore their
made to help families thrive by providing family-centered
interest and opportunities in the field of rheumatology
care, using AbbVie’s significant charitable donations.
• An educational award-winning program in inflammatory We provided financial support to nonprofit partners addressing
bowel disease that improved patient outcomes by addressing challenges that directly affect a family’s emotional, psychological
specific unmet educational needs in gastroenterology and financial well-being during a child’s illness.
• A digital health coaching program that helps patients live
well with their disease
Bolstering Partners to Support Sick Children and Their Families

In 2018, AbbVie made a historic donation to Ronald patient advocacy, transportation, lodging and more. CDLA
McDonald House Charities (RMHC) to help provide families also supports patients’ continued education, offering on-site
the comforts of a “home away from home” while their child classes for younger children and subsidizing transportation
is hospitalized. In 2019, this support helped RMHC to offer to and from school for older students who remain able
new family-centered services to connect with communities to attend classes. Patients receiving CDLA support have
at an additional 32 chapters. Essential social support services demonstrated improved adherence and decreased mortality
provided at RMHC Houses ensure the entire family – from rates, nearly 50 percent lower than the national average. In
child patients to parents to siblings – is cared for and 2019, the program’s fourth year, CDLA supported 613 children
comfortable, allowing the family to focus on healing fighting cancer and their families and caregivers.
and wellness.
AbbVie’s $5 million donation in 2018 enabled Family Reach,
In Mexico, the AbbVie Foundation is supporting Direct a national organization dedicated to eradicating financial
Relief’s Pediatric Cancer Family Support Program to address barriers for families facing cancer, to serve 25 additional
barriers, including non-medical challenges to pediatric hospitals in 23 states. This expansion helped more than
cancer care. Direct Relief and local organization Casa de la 2,900 additional families in immediate need.
Amistad (CDLA), or “House of Friends,” help families navigate
their child’s cancer care, providing psychosocial support,
“AbbVie’s unwavering support has

been game changing for the cancer
care community.”
– Joan Russo, Vice President of Development,
Family Reach
“Even in the most difficult moments …

we had our family at Casa de la
Amistad for emotional support.”
Photo Credit: Direct Relief – Natali, mother to six-year old CDLA resident Leonardo
Building and supporting a diverse,

high-performing workforce
For an innovation-driven company like AbbVie, the knowledge, ideas and
capabilities that employees bring are critical. We’re focused on attracting,
In this section:
retaining, developing and supporting the people who, working together, can
We promote a diverse, inclusive
advance our mission.
workplace and invest in capability
Embracing equality, diversity and inclusion (ED&I) is fundamental at AbbVie. development to drive innovation
We know that the best ideas can come from anywhere in the organization, so
employees must be comfortable sharing their perspectives and challenging We protect human rights and
each other. workplace safety
To maximize the performance of individuals and teams, we must help them
build the capabilities that are most critical to our mission and success. We We offer our people the resources
must also treat them with respect, provide a safe environment and support and support they need to be at their
their well-being. personal best every day
We promote a diverse, inclusive workplace and

invest in capability development to drive innovation.
Evidence shows that equality, diversity and inclusion (ED&I) We provide resources for the learning and development of all
in the workplace help to drive superior business performance. employees. Our year-long signature global program, Learn.
We embrace diverse backgrounds and perspectives and treat Develop.Perform. (LDP), utilizes webinars, online tools and
everyone equally, with dignity and respect, allowing us all to mobile resources to help close development gaps and identify
achieve our collective best. the skills our leaders need. In 2019, more than 70 percent of
global employees regularly engaged with LDP resources.
Our CEO and executive leadership team oversee and take
accountability for our ED&I strategy, actions, measurements In addition, functional organizations have dedicated learning
and results. and development teams that provide training on function-specific
knowledge and skills.
Activating this strategy helps us innovate, understand our
customers and attract and retain the best talent. We proactively Our diverse and committed employees contribute in many ways
engage talent from diverse backgrounds. A range of global to the economic and cultural vitality of their communities. We
programs ensures we attract and hire a diverse workforce, create business opportunity for thousands of suppliers in more
including women, people from all backgrounds and ethnicities than 131 countries and all U.S. States, the District of Columbia
and people with disabilities. and Puerto Rico. Since 2016, we have conducted more than
130 detailed assessments of labor, health and safety in North
To support our diverse workforce, we must create an
America. Our Supplier Diversity program is designed to integrate
environment where all individuals can thrive. This means
small and diverse businesses into our supply chain. We offer
educating and engaging employees and leaders about inclusion.
opportunities for historically underutilized populations, including
Our functional ED&I Councils and Employee Resource Groups
underrepresented populations, women, military veterans and
(ERGs) promote awareness and appreciation of our diversity,
others, to do business with AbbVie.
ensuring people of all backgrounds can develop and thrive.
At AbbVie, our Talent Philosophy is the foundation of all that
we do to drive performance. There are five elements that guide
our thinking about talent and leading at AbbVie: Performance,
Behaviors, Differentiation, Accountability and Transparency. Top
talent is defined as employees who demonstrate all of these
elements consistently over time.
Employee Resource Groups (ERGs)

Our progress
In 2019, we implemented our new global ED&I strategy
across the organization. This includes a five-year roadmap that
defines key global focus areas, objectives, associated initiatives
and implementation plans by function and geography. Our senior
leaders have taken formal 2020 goals aligned with executing
this strategy.
“At AbbVie we strive to create an

inclusive culture where everyone is
treated equally, with dignity and respect.
When our employees embrace diverse
backgrounds and perspective, we are
all able to achieve our very best.”
– Julie Osborne, VP, Equality, Diversity and Inclusion Expanded ED&I team
ED&I Strategic Pillars

Drive Awareness Attract & Source Develop & Engage Create Connections Build ED&I
& Understanding Talent Talent & Community Employer Brand
Instilling an inclusive Proactively finding and Creating opportunities Bringing people Positioning AbbVie as
mindset in all leaders engaging top talent for talent to thrive together to promote an inclusive employer
and employees inclusion of choice
To help drive awareness and understanding, we We continued to create connections and a sense of
implemented key initiatives. We held small group community through our ERGs. AbbVie was proud to
listening sessions where employees had the opportunity to introduce a new ERG, Ability at AbbVie, to support employees
listen to ED&I strategies and offer valuable feedback and ideas. with disabilities, employees who have children with disabilities,
In the U.S., we added Martin Luther King Jr. Day as a paid caregivers and allies.
company holiday. Across the globe, we exhibited our belief
that “Love is Love” by raising the Pride flag at multiple AbbVie
locations. We were proud to host multiple cultural celebrations
for Black History Month, Women’s Equality Day, Hispanic
Heritage Month, Diwali, Kwanzaa, Veterans Day and more.

Equality, Diversity and Inclusion 2016 2017 2018 2019
Total employees 28,939 29,777 30,612 30,776
Female share of total workforce 52.9% 53.4% 53.2% 53.3%
Females in management positions 44.7% 46.9% 47.1% 48.0%
Females in top management positions (up to CEO -2) 35.0% 37.9% 34.8% 34.6%
Females on the Board of Directors 1/9 2/10 3/11 3/11
Proportion of U.S. employees who are members of – 30.1% 31.4% 32.0%
underrepresented populations*
Proportion of U.S. employees who are veterans* 3.2% 3.4% 3.8% 3.8%
Proportion of U.S. employees who have disabilities* 0.9% 1.2% 1.2% 1.2%
Except for total employees, figures exclude Pharmacyclics. *These figures are based on employee self-reporting.
In 2019, we focused on attracting and sourcing talent by

launching formal partnerships with two historically black
colleges and universities, Howard University and Florida A&M.
We also provided emerging student leaders with opportunities
for career development, mentoring support and to be immersed
in our AbbVie culture.
We continued to develop and engage our talent through
initiatives such as our global Women’s Leadership Journey,
which provides a broader awareness of and exposure to the skills
and perspectives needed to excel into senior roles. Since its
launch in 2018, 72 women have completed the program, with
37 percent representation from multicultural women.
Our Executive Diversity Mentoring Program (EDMP) aligns
diverse key talent with our top 34 executive leaders for
a one-year partnership. In its fifth year, women comprised
58 percent of U.S. EDMP participants, and 33 percent were
multicultural women. In 2019, 25 percent of EDMP mentees
were promoted.
Talent Attraction, Retention & Development 2016 2017 2018 2019
Overall turnover rate 9.2% 8.4% 8.6% 11.1%
Voluntary turnover rate 5.9% 5.3% 5.5% 6.6%
Employee engagement rate* 81% — 84% —
Percent of employees who indicate that AbbVie equips them 76% — 79% —
well to perform in their role*
*Source: Employee Survey, which is conducted every two years. Percentage favorable responses (“agree” or “strongly agree”) to the following questions:
• I have the tools and resources to do my job well.
• I have opportunities to learn new skills that help me succeed.
In 2019, we purchased goods and services valued at In 2019, AbbVie was named Corporation of the Year by
more than $13.8 billion from suppliers around the world. Diversity Alliance for Science, in recognition of our ongoing
This included more than $930 million from approximately commitment to mentorship and development of small and
2,000 small and diverse businesses in North America, diverse suppliers.
including Puerto Rico. Our Environmental, Health and Safety
team, in partnership with our office of Supplier Diversity,
offers support to small and diverse suppliers with pro bono
services including environmental, health and safety (EHS)
audits and sustainability training. Other supplier development
activities consist of annual mentoring on a variety of topics
by our experienced teams..

Supplier Spend and Diversity 2016 2017 2018 2019
Total supplier spend (worldwide) $8.2B $9.7B $13.3B $13.8B
Total spend with small and diverse suppliers (millions) $516 $741 $894 $934
Embracing Equality, Diversity and Inclusion Around the World

As part of our commitment to ED&I, AbbVie affiliates around the world are implementing programs that resonate with their
unique cultures and employee needs.
Brazil and Ireland: Committing to inclusion for all people with disabilities
Disability manifests in many forms, some not as readily In Brazil, the recently launched Equality, Diversity &
visible as others. We recognize that an environment where Inclusion Committee sponsors events throughout the year
all voices are heard and valued is vital to employees’ ability to celebrate disability awareness, raising the voices of those
to bring their best selves to work. with disabilities and striving to normalize their experience.
People managers have undergone training to disrupt bias
that can stigmatize people with disabilities.
“No one should feel like they can’t

ask for the help if they need it, – Jade Bradley, AbbVie employee in
Ballytivnan, Sligo, Ireland. Jade has
because at AbbVie they believe dyslexia and requested specific
in supporting you to perform to software to support her work. The
software was quickly added to our
the best of your ability and will resource library and is now available
support you on your journey.” for all employees.
Australia and New Zealand: Raising awareness for mental health in the workplace
Research shows mental health is one of Australia’s greatest In February 2019, AbbVie Australia and New Zealand
workplace challenges. In late 2018, AbbVie conducted launched a new mental health strategy. A key part of the
research, using both surveys and focus groups, to better program focused on providing employees with training, tools
understand the well-being of our workforce. The results and tactics to improve their mental health, help manage
showed that few staff felt comfortable talking about their stress and help employees better facilitate open and honest
mental well-being with colleagues, and that there was an conversations about mental health in the workplace. A
immediate need to destigmatize issues around mental health. follow-up survey has demonstrated that this new mental
health strategy has given many more employees the
confidence to speak openly about their mental health.
Japan: Increasing workplace flexibility to support families

Many teams across affiliates are introducing flexible work policies to accommodate the personal needs of employees. AbbVie
Japan has introduced an “Anytime, Anywhere” policy to increase flexibility for employees needing to care for family members.
Takashi Nishimura took Fumiyo Aoki was able to care

paternity leave, which is for her aging parents who
very uncommon in Japan, live far from Tokyo. With the
and was able not only to support of her manager and
provide childcare for his team, Fumiyo was given the
young son, but also to shift time and space needed to
the image of paternity leave provide for their needs at a
in his community. critical time.
Commitment: Steward our ethical and sustainable business
We protect human rights and workplace safety.

We recognize that we are part of a broader ecosystem of Our progress
partners and collaborators. The lives of our employees and
the lives of those we touch through our work at AbbVie are the
In 2019, we continued to lead the industry in employee
most important part of our business and we are committed to
health and safety. Since our launch as an independent
protecting their fundamental human rights. We believe in the
company, we have been the Dow Jones Sustainability
inherent dignity of every human being. We uphold and respect
Index (DJSI) leader in occupational health and safety across
individual rights as set out in the Universal Declaration of
the biotechnology industry, reflecting our commitment to
Human Rights, focusing on preventing, mitigating and remedying
continuously improving our best-in-class safety programs.
any adverse human rights impacts across our value chain. Our
Commitment to Human Rights describes the ways in which We demonstrated our commitment to workplace safety through
we ensure respect for all people, including our employees, initiatives such as the STOP Program for Frontline Supervision,
contractors, suppliers and patients. a safety training observation program designed to reduce
workplace injuries and illnesses through training, peer-to-peer
Ensuring the safety of our employees across our workplaces
support and coaching. This program aligns with our culture of
is one of our cornerstone commitments to human rights.
risk anticipation and is intended to improve our detection and
We provide comprehensive workplace safety training for all
elimination of EHS incidents. To date, more than 650 supervisors
employees, as appropriate for their environment. Our guiding
have received training globally.
philosophy is called Zero. Believe It. Achieve It., which reflects the
core belief that every environmental, health and safety incident is We also continued our involvement with the Pharmaceutical
preventable if each employee adopts a preventative mindset. Supply Chain Initiative that promotes responsible practices
in labor, health, safety and environmental sustainability in
We also obtain external certifications for workplace safety. All
supply chains.
of our manufacturing sites are certified to the international
standards for safety associated with OHSAS-18001 (three sites) In 2019, we updated our anti-harassment training in the U.S.,
or ISO 450001 (nine sites). All OHSAS-18001 certified sites will administering new training modules for both employees and
move to ISO 45001 by end of 2021. managers. A total of 13,865 employees received the training.
Workplace Safety 2016 2017 2018 2019

Recordable incident rate (per 200,000 hours worked)* 0.30 0.28 0.27 0.25
Lost time incident rate (per 200,000 hours worked)* 0.10 0.06 0.05 0.09
* Data reported in 2016-2018 has been restated due to changes in classification of injury/illness cases post year.
Periodically, cases will change Recordability or Lost Time status based on medical case management.
Commitment: Support long-term community strength
We offer our people the support they need to be at

their personal best every day.
To be effective at work, employees must also be able to meet • On-site health screenings and immunizations in several
their personal, family and community needs and obligations. countries
That’s why we provide programs to support employee health, • On-site fitness and rehabilitation centers
well-being and work-life balance.
• AbbVie in Motion, a four-week global team competition
Our comprehensive and competitive suite of benefits ranges encouraging fitness and resilience. In 2019, nearly 8,200
from medical and dental coverage to retirement, disability and employees in 59 countries participated in AbbVie in Motion,
life insurance programs. logging an average of 20 hours of exercise per employee over
the course of the program.
AbbVie Vitality is our approach to employee well-being. The
program encompasses a wide range of local and global events, • AbbVie World of Well-Being, a global health awareness
programs, resources and tools including: program that offers activities to improve employees’ overall
health, well-being and performance, including a variety of
• Seminars and online resources on health-related topics, such
local events. Employee engagement has grown more than
as stress management, nutrition, safety and work-life balance
10 percent since 2018.
• Health promotion programs, including for diabetes, cancer
and weight management We also support work-life balance and flexibility to help
our employees sustain high performance, productivity and
• Mental health awareness campaigns and employee
engagement. We provide managers and their teams with tools,
assistance programs in several countries
tips and guidelines on effectively managing workloads, managing
• Financial and well-being support, including retirement teams from a distance and supporting flexible work practices.
programs and online and in-person learning and seminars
• Heart-healthy offerings and campaigns in many company
cafeterias
Our progress
In 2019, we continued our focus on the well-being of We received a Gold distinction from Best Employers:
our employees and their families. We encouraged our Excellence in Health & Well-being. Awarded by the
employees to ask for help, whether in their personal or National Business Group on Health, this award recognizes
professional lives. AbbVie implemented the Family Care the best workforce well-being programs in the U.S., particularly
Navigator program on March 1, 2019, a customized advocacy those with a holistic approach to well-being, encompassing
program that helps U.S. employee members navigate their financial, emotional, social and community aspects. It further
mental health benefits with special focus on accessing pediatric recognizes a connection between employee well-being and
care, including a primary contact to manage cases and provide key business outcomes.
patient advocacy.
We also have industry-leading parental leave policies and
We continued our focus on mental health through an on-site daycare to support our working parents. In addition,
awareness campaign in May 2019 in alignment with all U.S. employees are permitted to use up to two days of paid
Mental Health Awareness Month in the U.S. The goal of the work time to volunteer in the community.
campaign was to provide information and statistics on common
In 2019, the AbbVie Employee Assistance Fund (AEAF)
conditions (e.g., anxiety, depression, substance abuse disorders)
became fully operational, working to support our employees
affecting many adults and adolescents in an effort to eliminate
around the world. The AEAF funds programs that offer
the stigma and guide employees to help. We reinforced the
employees assistance at two pivotal moments – when a child
availability of AbbVie and external resources, including the
goes to college and when disaster strikes. The goal of the AEAF
Employee Assistance Program, that employees, as well as their
is to offer resources to employees and their families when they
spouse/domestic partner and dependents, can use for support
need it most.
and financial assistance.
The AbbVie Employee Assistance Fund: First Year of Operation

AbbVie Possibilities Scholarship Program Employee Relief Program
The AbbVie Possibilities Scholarship is offered globally to We know that day-to-day life can be negatively impacted by
children of AbbVie employees. Students may apply for an circumstances outside of our control. When the unexpected
annual merit-based scholarship of up to $5,000 for use at happens – a disaster or personal hardship – employees can
accredited colleges, universities or vocational-technical access financial assistance through our Employee Relief
schools. In the inaugural year of the program, over 300 Program. The program helps ensure the safety and well-being
scholarships were awarded to children of AbbVie of our employees around the world. In its first 8 months, the
employees from 25 countries. program provided financial assistance to employees from
over 12 countries.
“Despite their humble lives, my parents
achieved their dream. Now, I pursue “AbbVie’s generosity reaches across
mine, with my parents as inspiration.” the organization and demonstrates that
– Scholarship Recipient, Mexico caring for those who contribute daily is
a core value they honor and act upon…
As an employee, knowing that there is
hope and support when coping with
and managing through an unexpected
life-event is priceless.”
– U.S. field-based employee
Parents of AbbVie Possibilities Scholarship Program recipients

Making positive contributions

to society
As a biopharmaceutical company, our opportunity to make positive
contributions to society starts with the innovative medicines we discover,
In this section:
develop and deliver. Making them accessible to patients who need them is a
We give our medicines, expertise
critical part of our contribution. However, for people without reliable access to
health care services, medicines alone aren’t enough. That’s why we support and funding to address the health
community-based programs that enhance access to health care more broadly. needs of the underserved
We also know that good health requires a healthy environment and that We prioritize environmental
climate change will increasingly impact human health. We hold ourselves sustainability across our business
accountable for sustainably running our business and reducing our impact on
the environment.
and supply chain
Giving back is an integral part of who we are. We recognize that a corporation We support communities through
with global scale and unique resources has the responsibility to use those economic activity, employee
resources for social good. That’s why we encourage our employees to be community engagement and
engaged with their communities and support their volunteerism. And it’s why
philanthropy
we provide philanthropic support to build long-term community strength.
We give our medicines, expertise and funding

to address the health needs of the underserved.
At AbbVie, we believe patients need access to quality and We contribute to the World Intellectual Property Organization’s
affordable medicines. We continuously strive to improve health Patent Information Initiative for Medicines (Pat-INFORMED)
outcomes and increase access to health care services and our database, which is designed to help facilitate access to
medicines for patients around the world. AbbVie partners with medicines globally. The database provides patent information
stakeholders on interventions to help build health care capacity, on medicines for HIV/AIDS, cardiovascular diseases, diabetes,
increase the quality and frequency of health worker training hepatitis C, oncology, respiratory conditions and other products
and educate patients about disease awareness, symptom on the WHO Essential Medicines List.
management and treatment options.
Through our medicine donation programs, we provide medicines
Our approach to access is tailored on a product- and country- for people who would have no other means of accessing
specific basis. We consider a range of factors including local them. We have seven ongoing medicine donation partnerships
disease burden, health and economic value of the medicine, with organizations providing care in low- and middle-income
ability to pay and budget impact and other factors impacting countries. We support access to surgical care by donating our
disease-specific outcomes, as well as the sustainability of general anesthesia treatment for use in free surgeries. We further
different access strategies for the countries’ health care system donate medicines for use in disaster relief efforts and in response
and our business. With these factors in mind, we utilize a to humanitarian crises. Since 2013, we have donated medicines
number of strategies to address access-related issues including for use in over 100 countries.
pricing and reimbursement models, patient financial assistance
We also partner with nonprofit organizations working to
programs, intellectual property licensing, product donation and
strengthen health systems. The AbbVie Foundation supports
support for local capacity-building programs.
community-based programs that enhance access to health care
Our commitment to acting responsibly extends to drug pricing. for the underserved.
AbbVie evaluates specific pricing decisions on an annual basis
with careful consideration of a variety of factors. Since 2017,
AbbVie has publicly committed to taking no more than one
single-digit price increase.
Since 2013, the AbbVie Foundation has supported the Baylor College of Medicine
International Pediatric AIDS Initiative (BIPAI) in providing a holistic approach to HIV care
and treatment, including prevention, comprehensive medical care and psychosocial support in
Romania and Malawi.
The AbbVie Foundation continues its long-term partnership with AMPATH (the Academic
Model Providing Access to Healthcare), seeking to make health care achievable and
sustainable in Kenya by helping to advance the vision of universal health coverage for all Kenyans
and developing an integrated approach to care that serves hard-to-reach populations and
addresses multiple health challenges.
The AbbVie Foundation similarly supports Partners In Health’s innovative community health
programs, which strengthen the capacity of community health workers in parts of Mexico and
Peru. Support from the AbbVie Foundation has enabled Partners in Health to add four new clinic
service areas to its community health worker program in Mexico.
Complementing AbbVie’s pro bono research program on neglected tropical diseases, the
AbbVie Foundation maintains a long-term partnership with MAP International, supporting their
multi-faceted, community-based approach to Chagas disease prevention and management in
Bolivia, which includes training community health workers, health education and diagnosis and
treatment support.
Our progress
In 2019, we expanded our U.S. patient assistance program, We established an innovative partnership with the U.S. state
which provides free AbbVie medicines to qualifying patients. of Washington to help eliminate hepatitis C in the state.
We gave the program a new name, myAbbVie Assist, expanded The collaboration includes a modified subscription-type pricing
eligibility for the program, simplified the application process and model for our pan-genotypic medicine, complemented by AbbVie
conducted an awareness campaign to ensure that qualifying support for a range of initiatives designed to help find, screen
patients knew of the program. myAbbVie Assist provided free and link patients to treatment, and advance the knowledge
AbbVie medicine, including many of our newest medicines, to and skills of nurses on the front lines of the elimination effort.
over 89,000 patients in 2019, up from nearly 81,000 patients in Globally, AbbVie supports approximately 300 micro-elimination
2018. Information about eligibility for myAbbVie Assist and other projects focused on eliminating HCV in targeted populations or
savings programs is available at abbvie.com/patients. geographies. Many of these programs are helping to address
challenges key populations face in accessing care.
In China, QC Tools, a suite of HIV/AIDS case management
tools developed with AbbVie support, achieved adoption
by 18 provinces that collectively house 90 percent of the “We were looking for a partnership
country’s HIV/AIDS patients. QC Tools is part of an approach because we really want to break
developed collaboratively with Chinese health organizations and
provincial AIDS administrators to help China address a surge through these barriers. It’s not just
in HIV/AIDS patients by sharing information to get them into about the price of a treatment; we
treatment faster. In 2019, we also worked with China’s largest
health publishing group to build a series of smartphone-based
need help across the entire spectrum
e-learning platforms called AIDS Hub, which provides information of care. That’s why we’re really excited
to health care providers to address the growing needs of their by the experience and support that
patient populations. Within three months of its initial launch,
AIDS Hub published 532 courses and registered 4,100 health AbbVie brings to the table.”
care providers. Together, these tools are helping China progress – Judy Zerzan, M.D., Chief Medical Officer,
toward 90-90-90 targets set by the Joint UN Programme on HIV Washington State Health Care Authority
and AIDS. Read more about the targets here.
We engaged with key policymakers, scientists, clinicians
and patient leaders in dialogue about how to build, fund
and implement successful cancer control programs at The
Economist’s 2019 War on Cancer event in Mexico City.
AbbVie sponsored a panel discussion on the needs of patients
with blood cancers, to help ensure they are part of the public
health agenda and addressed in the national cancer plans
being developed by the government of Mexico. AbbVie is
collaborating with the Mexican Institute of Social Security to
further document the burden of blood cancers in Mexico, and
with local patient organizations on policy briefs to further inform
national cancer plans.
Expanding access to health care and our medicines 2016 2017 2018 2019
U.S. patients provided medicine at no cost through the myAbbVie Assist patient 78,745 76,692 80,871 89,122
assistance program
Commitment: Steward our Ethical and Sustainable Business
We prioritize environmental sustainability across our

business and supply chain.
At AbbVie, we believe in the importance of a healthy environment We also expect our suppliers to join us in our efforts to protect
and the sustainable use of natural resources. We work to the environment. As stated in our Supplier Code of Conduct,
advance the sustainability of our global operations by reducing we expect that “suppliers shall operate in an environmentally
the energy and water we consume, and by reducing the waste efficient manner and shall strive to minimize adverse impacts
we generate. We also monitor our operations to ensure that the on the environment.” Our supplier sustainability audits include
manufacture, use and disposal of our medicines do not adversely a robust assessment of the environmental stewardship practices
affect the environment or human health. of key suppliers.
We use robust environmental and energy management systems. Through our sustainable procurement policy, we prioritize
All of our manufacturing sites have ISO 14001 certification for the selection of suppliers and purchased goods that have
effective environmental management systems, ten have ISO lower impact on the environment when compared with
50001 certification for effective energy management systems and competing products.
we are working toward two additional ISO 50001 certifications.
View our commitment to environmental stewardship and our
We have set ambitious, long-term environmental sustainability position on global climate change for additional information.
targets for absolute reductions to carbon emissions, water use
and waste generation, striving for zero waste to landfill at our
sites, while driving increases in renewable electricity. Through
participation in CDP, we are transparent about our efforts and
our impacts.
AbbVie environmental targets (all changes are relative to 2015 baseline)
2025 Target 2035 Target
Reduce absolute carbon emissions (scope 1 & scope 2 – market based)

Increase
25% 50%
Renewable Reduce absolute total
Reduce absolute
Electricity Water Withdrawal
Carbon Emissions
25% Increase50%
(Scope 1 & Scope 2 –
market based) 20% purchased from renewable sources
percentage of electricity
Percentage of electricity purchased
(including non-contact
cooling water)
50% 100%
(excluding leased commercial offices)
from renewable sources, excluding
leased commercial offices
Increase
Renewable Increase
Renewable
Reduce absolute total
Electricity
Reduce absolute
Water Withdrawal
Electricity
Reduce absolute total
ons
Scope 2 –
ed)
50%
Carbon Emissions
25% 50% water withdrawal
Reduce20%
absolute
(Scope 1 & Scope 2 –
market based)
Water Withdrawal
20% (including non-contact cooling water)
cooling water)
cooling water)
20% 50%
fromReduce absolute total
renewable Percentage of electricity purchased
Increase Achieve
Reduce absolutesources,
total excluding
Waste Generated Recycling Rate
Water Withdrawal
from renewable sources, excluding
Zero Waste
20%
20%
Increase
Renewable 50% Landfill to
100%and non-hazardous waste generated

chased
missions
Electricity Reduce absolute
Hazardous & water)
cooling
Non-Hazardous Waste total hazardous
Water Withdrawal
Reduce
Combined absolute
Recycling
Hazardous &
total
Rate for
20% —
50% (excluding20%
cluding
(excludes leased offices)
(excluding construction and Non-Hazardous Waste
ope 1 & Scope 2 –
rket based)
demolition waste)
construction and demolition waste)
Increase
fromabsolute
Reduce renewable
totalsources, excluding
(excluding construction and
demolition waste)
Achieve
cooling water)
Increase Achieve
ted Recycling
Waste
Reduce Rate
Generated
absolute total Zero WasteRate
Recycling Zero Waste
50%
20%
Water Withdrawal 50%
to Landfill to Landfill
ste 20%
Hazardous
Combined
Hazardous
Achieve
&(including
Recycling Rate
& cooling
Non-Hazardous
for
Achieve100%
non-contact
Waste
water)
and maintain 100%
combined recycling rate for hazardous & non-hazardous
Combined Recycling Rate for
Hazardous &
50% —
te
urchased
Zero WasteWaste
Non-Hazardous (excludes leased offices)
Non-Hazardous Waste
waste (excluding construction and demolition waste)
xcluding
demolition
(excluding waste) and
construction (excluding construction and
to Landfill
demolition waste) demolition waste)
100%
l Increase Achieve
nerated Recycling Rate Zero Waste
aste 50%
(excludes leased offices) to Landfill
us Waste
Combined Recycling Rate for
Hazardous &
Non-Hazardous Waste
100%
Achieve zero waste t o landfill (excluding leased offices)
— 100%
ion and
Achieve
ate Zero Waste
demolition waste)
to Landfill
or
Waste
100%
nd
Our progress
2019 marked the inaugural year for a new environmental We reduced water consumption through continued
sustainability strategy focused on reducing our investment in new technology. At our North Chicago sites,
environmental footprint, growing sustainably and we implemented a new process for generating purified water
inspiring, educating and engaging our workforce to steward for our manufacturing operations, resulting in annual projected
sustainability within and beyond AbbVie. The strategy is reductions of over 110,000 cubic meters (25 million gallons) of
grounded in three key pillars: operate responsibly, sustainable water consumption. Using new meters, the team at our Sligo-
growth and innovate and inspire. We have made notable progress Manorhamilton site in Ireland has identified water-saving projects
this year in each area of focus. delivering over 28,000 cubic meters of water savings annually.
We have continued to make progress on our absolute We completed two significant waste reduction projects in
environmental sustainability targets relative to our 2015 2019. By installing an on-site wastewater treatment unit at our
baseline. Since 2015, we have reduced our absolute carbon Sligo-Manorhamilton site, we are able to remove all of the active
dioxide emissions (scope 1 and 2) by more than 16 percent, pharmaceutical content from the cleaning process wastewater,
over halfway to our 2025 target of 25 percent. We increased the resulting in an estimated 70 percent reduction in hazardous
percentage of purchased electricity from renewable sources waste generated at the site going forward. We also completed
to more than 24 percent, up from 9 percent in 2016 and almost a non-hazardous waste reduction project at our North Chicago
halfway to our 2025 target of 50 percent. site that allows us to repurpose a portion of the waste for offsite
Reduction in carbon emissions is being achieved largely beneficial use, resulting in an estimated annual reduction of 740
through investment in technology, infrastructure and metric tons (1.6 million pounds) of waste to landfill.
processes to increase energy efficiency. In our Barceloneta, As we seek to grow our business, we are taking steps to
Puerto Rico plant, we installed a new combined heat and energy ensure we are incorporating environmental sustainability
system that is more energy efficient and reduces SOx, NOx and into our plans and programs. Over the past year, we have
particulate matter emissions. We continue to expand the use of updated our Global Facility Design Guidelines to integrate
electric and hybrid vehicles in our fleets. We also increased the more than 100 environmental sustainability opportunities and
amount of renewable electricity that we purchased to power sites best practices applicable to new, renovated and leased AbbVie
in North America. buildings worldwide.
Environmental Sustainability 2016 2017 2018 2019
Change in absolute carbon emissions vs. 2015 baseline* -8% -13% -13% -16%
(scope 1 and scope 2, market based) [2025 target: -25%]
Change in absolute water withdrawal vs. 2015 baseline* +4% +1% +4% -6%
(includes non-contact cooling water)++ [2025 target: -20%]
Change in absolute water consumption** vs. 2015 -5% -12% -11% -12%
(excludes non-contact cooling water)++
Combined recycling rate for hazardous and non-hazardous waste 37% 37% 32% 35%
(excluding construction & demolition) [2025 target: 50%]
Percentage of global waste diverted from landfills (annually) **,+ 77% 83% 85% 88%
(excluding construction & demolition)
Percentage of electricity purchased from renewable sources 9% 16% 20% 25%

(excluding leased facilities) [2025 target: 50%]
*Figures exclude two R&D facilities which were not included in the 2015 baseline.
**This key performance metric includes manufacturing and R&D, which account for the majority of our operations.
+Includes waste disposed of in the following manner: beneficial use, recycled, composted, treated, fuel blending, incinerated with energy recovery and incinerated without energy
recovery.
++Non-contact cooling water is returned to the source in the same amount and with the same quality as was withdrawn. The increase we’ve seen in our non-contact cooling water
use is generally due to seasonal variations in source water temperatures.
Spark: Inspiring AbbVie Employees Ingraining Sustainability into Our

to Innovate for Sustainability Work Across Ireland – Both Inside
Our global workforce is one of our most powerful tools in and Outside the Office
driving sustainability through our operations and beyond. Ireland is home to three AbbVie manufacturing sites in Cork
To harness their ideas, in 2019, we launched the Spark and Sligo and two offices in Dublin. Our Irish workforce,
Innovation Accelerator, an internal incubator for employee- which comprises more than 700 employees in all, has taken
driven sustainability proposals focused on accelerating a leadership position on sustainability.
our efforts to reduce energy, water and waste.
Established in 2019, Team Evergreen, the affiliate’s cross-
Our Global Sustainability and Business Technology site, cross-functional working group focusing on “green”
Solutions teams recognized the need the explore more solutions, has already implemented a number of highly
innovative sustainability solutions and the heightened impactful initiatives at our operations and commercial
interest among the broader base of AbbVie employees sites. The group is focused on identifying, implementing
in being part of our sustainability efforts. and sharing best practices across sites, within their
communities and with other affiliates.
Spark Innovation invites employees across the
enterprise to submit proposals for new ways to reduce Team Evergreen’s work has been celebrated by a
AbbVie’s environmental impact and help us achieve our number of national, regional and international groups,
environmental sustainability targets. demonstrating excellence in terms of sustainability and
environmental awareness-raising. Recent accolades
The response to Spark Innovation has been tremendous.
include Facilities Management Award for CSR Initiative of
In this first year, more than 130 individuals from over
the Year, Pharma Industry Awards Company of the Year
20 sites submitted a total of 110 ideas. Bringing both
and American Chamber of Commerce in Ireland Créafóg
cross-functional expertise and passion, they volunteered
(earth) Award.
their time to developing impactful proposals.
AbbVie
The winning ideas represented teams from Chicago, Puerto
Rico, Ireland, Germany and Singapore. Each winning team
is piloting its ideas and sharing monthly progress on a
global website for all employees to follow along.
Evergreen
...sustaining our business
Members of the Spark Innovation Steering Committee review

finalist pitches
Team Evergreen members alongside newly installed electric car

charging ports
Commitment: Steward our Ethical and Sustainable Business
We support communities through economic activity,

employee community engagement and philanthropy.
At AbbVie, involvement in our communities covers a spectrum We work with critical partners toward these ends. For example,
of engagement. Not only do we provide funding to nonprofits we’ve established a long-term relationship with North Chicago
through the AbbVie Foundation, but we apply our hands and Community Partners (NCCP), an organization whose mission
minds to serve our communities. is to address the lack of support for academic challenges
facing children in this under-resourced community. Through
Since the company’s inception in 2013, AbbVie and the AbbVie
NCCP, AbbVie provides support, financial and otherwise, to
Foundation have contributed significant funding directly into the
strengthen the community holistically – from nurturing students
North Chicago community immediately surrounding our global
academically, to bolstering health and social services.
headquarters. Through the work of more than 30 local nonprofit
organizations, our contributions have helped to build the district’s In China, employees worked with the Shanghai Children’s
first preschool, renovate libraries, classrooms, athletic facilities Medical Center, where children are undergoing treatment for
and activity rooms and fund the adoption of new math and serious illnesses. Even though the hospitalized children face
reading curricula. life-threatening diseases, their desire to learn remains strong.
Natural disasters can cause injury, illness, death, homelessness The AbbVie Foundation’s SEEK (Science, Engineering,
and economic loss. Through our disaster relief program, we help Exploration, Knowledge) program introduces children ages
communities recover from disasters and become more resilient 5–14 to science and engineering with the goal of filling the gap
for the future. Our program has helped communities impacted by in STEM education around the world. In China, employees
nearly 50 disasters in more than 25 countries on 6 continents. worked with the Shanghai Children’s Medical Center, where
children are undergoing treatment for serious illnesses. Even
Our North America employee giving and matching program
though the hospitalized children face life-threatening diseases,
encourages employees to make charitable donations to eligible
their desire to learn remains strong. SEEK has enhanced the
nonprofit organizations. Through an online platform supported
education of close to 300 children in Asia, primarily in classrooms
by AbbVie, employees, retirees and former and current
and hospitals across four major cities in China and in Japan
members of the Board of Directors may make contributions
starting in 2016. AbbVie scientists shaped the SEEK curriculum,
to charities of their choice. The AbbVie Foundation matches
with a group of female engineers developing the engineering
those contributions dollar for dollar, up to $5,000. Each year we
module and advocating for robust curriculum. Today, the program
run the Employee Giving Campaign to encourage participation
is offered in 12 languages across multiple countries, including
in the program. We consistently exceed 85 percent employee
Brazil, China, Colombia, Germany, Japan, Malawi, Singapore,
participation in the campaign.
Switzerland, Vietnam and the United States.
Community engagement is an integral part of AbbVie’s culture
Through our spectrum of employee engagement, from giving
and we encourage our employees to give back through
and matching to hands-on and skills-based volunteering, we
volunteering. About one quarter of AbbVie employees volunteer
have harnessed the power of our global employee base to make
annually through programs sponsored by AbbVie or the AbbVie
a difference throughout the world.
Foundation. In recognition of this culture, Great Place to Work®
and PEOPLE named AbbVie as one of PEOPLE’s “50 Companies
That Care.” AbbVie ranked No. 25 on this list that highlights the
top U.S. companies that have succeeded in business while also
demonstrating outstanding respect, care and concern for their
employees, their communities and the environment.
AbbVie employees engage with students in their communities
through educational programs sponsored by the AbbVie
Foundation. In North Chicago, the AbbVie STEM (Science,
Technology, Engineering, Math) Challenge was developed in
partnership with the Illinois Science and Technology Institute to
enable students from the local high school to explore potential
careers in science.
Our progress
In its sixth year, our signature global volunteer event, Week Without a lawyer, non-detained asylum seekers prevail in only
of Possibilities, saw AbbVie employees in 50 countries 13 percent of cases, while legal representation increases their
donate more than 40,000 hours of community service. chances of success to 74 percent. On July 1, 2019, the Chicago
Through that event and other projects throughout the year, Asylum Office granted permanent asylum to one of our pro bono
AbbVie employees volunteered a total of 68,422 hours during clients. We are proud to be part of protecting human rights and
work time in 2019. In addition, over 12,000 employees – hopeful for more positive outcomes in the future.
85 percent of those eligible and triple the industry standard –
In 2019, AbbVie launched a pro bono program, Possibilities
participated in our North America employee giving and
Pros, with Taproot Foundation during Week of Possibilities,
matching program, generating $13.8 million to benefit more
pairing the minds of 50 employees with 11 local nonprofits to
than 6,000 charities.
walk through half-day design thinking session to address issues
Starting in 2018, through our legal pro bono program, such as marketing, project management, IT and human resource
AbbVie attorneys and legal staff have taken on 14 asylum challenges.
cases, donating their time and skills to represent people
As a committed employer in Puerto Rico, we were proud of
seeking asylum in the United States on grounds of political
the progress made by our partners, Direct Relief and Habitat
and gender persecution. They have teamed up with the
for Humanity, in moving the Puerto Rico community from
National Immigrant Justice Center (NIJC), a nonprofit that
recovery to resilience in the wake of Hurricanes Maria and Irma
provides legal services to immigrants and asylum seekers.
and the more recent earthquakes to hit the area.
AbbVie disaster relief contributions, 2013–2019
Australia Dominican Republic Honduras Malawi Pakistan Sierra Leone

Bahamas Ecuador India Mexico Peru Turkey
Balkan Islands Greece Indonesia Mozambique Philippines Ukraine
China Guatemala Japan Myanmar Puerto Rico United States
Colombia Haiti Liberia Nepal Serbia U.S. Virgin Islands
Education to Support the Whole Child

The United Nations Sustainable Development Goal (SDG) 4 focuses on ensuring quality education around the world. Supporting
educational programs and related services for school-age children is a philanthropic priority for AbbVie and the AbbVie
Foundation, and we are proud to partner with leading organizations in this space. In 2018, we deepened our commitment to
education in the U.S. by making a series of major donations. We are already seeing significant results from these partnerships.
Communities In Schools: Communities In Schools (CIS)

offers essential support services to provide at-risk students
“I see potential in
an equitable opportunity to excel in the classroom and [my student] – he
beyond. With AbbVie’s support, CIS expanded its reach to can serve as a
152 more schools, serving 100,000 more students, including
children in 16 high-need Chicago public schools. Through CIS leader at school
programs nationwide, students benefit from targeted support and at home.”
to help schools address chronic absenteeism, improve school
climate, close the opportunity gap and help students prepare – Rasnick F., CIS Chicago
for college and career. Student Supports
Manager
At a school in Chicago’s South Side, Rasnick F., known
affectionately by her students as “Ms. Razz,” provides ongoing Ms. Razz (Photo credit: Communities In Schools)
support through mentorship to 50 at-risk students.
The University of Chicago Education Lab: Through an “The only thing

AbbVie donation, the University of Chicago Education Lab
expanded its partnership with Chicago Public Schools, that we do is
supporting work to implement, evaluate and scale refuse to take no
promising solutions in education. In 2019, the Education
Lab partnered with nonprofit organizations across the city
for an answer.”
to pilot programs in nine alternative and neighborhood high – Chris Sutton, Program
schools, with the potential to impact thousands of students. Director, Youth Advocate
AbbVie’s support further allowed the Choose to Change Programs on C2C
program (C2C) – a partnership between Youth Advocate philosophy for its students
Programs, Inc. and Children’s Home & Aid – to expand
trauma-informed services to more than 200 students. Chris Sutton (Photo credit: Newsy—Jamal Andress and Madeline Carl)
Education Lab researchers found that youth who participate
in C2C experience a nearly 50 percent reduction in violent
crime arrests and have higher school attendance rates.
City Year: With AbbVie’s funding, City Year has significantly

expanded its work in STEM (Science, Technology,
Engineering and Math) programming as a result of AbbVie’s
partnership. City Year increased math and literacy support
in 58 more schools, reaching 45,000 students, and provided
new curricula and training services to more than 85 schools
nationwide. They are providing daily academic and social-
emotional supports for 226,000 students in 350 systemically
under-resourced schools across 29 cities during the
2019–2020 school year. Within AbbVie’s hometown of
Chicago, City Year expanded its impact in 31 schools,
serving 16,000 students.
City Year at work

Building Resilience in the Puerto Rico Health System

The 2017 hurricanes that ravaged Puerto The fruits of these investments are already visible. Following
Rico hit close to home for AbbVie. With a 6.4 magnitude earthquake in early January 2020, hundreds
more than 1,200 employees in Puerto of thousands of people across the island lost access to
Rico, we knew we wanted to be part of electricity and water. Health centers in the communities
both the immediate emergency relief effort receiving the new solar energy and water features were able
and longer-term community building. In to stay open with no interruption to patient care.
2018, AbbVie donated $50 million each to Direct Relief and
Through efforts to revitalize and strengthen the housing
Habit for Humanity International to strengthen Puerto Rico’s
system in Puerto Rico, Habitat for Humanity International
primary health care and housing systems, respectively.
completed 129 substantial home repairs, are currently
With AbbVie’s support, Direct Relief has implemented assisting in clearing 500 property titles and trained 194 local
numerous projects to help ensure uninterrupted care where workers in OSHA certified building practices, facilitating
it is needed most. further infrastructure improvements. In 2020, Habitat for
Humanity International will begin constructing new homes
Direct Relief repaired 14 health clinics damaged by Hurricane
to help rebuild the housing supply and support long-term
Maria, allowing them to reopen and expand operations in
resiliency.
partnership with local contractors. In 2019, Direct Relief also
procured and delivered a fleet of 17 Mobile Medical Units
and 17 Off-Road Patient Provider Vehicles to help health care
providers navigate challenging terrain and reach the most
remote and vulnerable populations. The Mobile Medical Units
are expected to reach 10,000 patients a year. Additionally,
Direct Relief launched a first of its kind telemedicine program
on the island. Through this program, Puerto Ricans can
access specialty care, such as mental health services, that
are often excluded from short-term emergency relief.
In the aftermath of Hurricanes Maria and Irma, a lack of
reliable power and access to clean water meant clinics could
not provide health services. To prevent a similar situation from
occurring in the future, Direct Relief is investing in resilient
power systems that combine solar power, battery storage
and backup generators to ensure continuous operation, even
through weeks-long disruptions of electricity. New solar power
installations support 12 health facilities and 14 community AbbVie employees prepared nearly 800 emergency backpacks for the
water pumps. To date, 1,800 families have benefited from the Medical Reserve Corps and other health care providers. Packs were
solar water pumps installed across the island. In addition, distributed following the January 2020 earthquake.
12,000 health workers from all health centers throughout the
island have been trained in emergency response procedures.
Economic activity, volunteerism and philanthropy 2016 2017 2018 2019
Employee community volunteers (worldwide) 8,174 7,247 7,494 10,059
Students reached through education projects 9,107 56,840 56,807 57,033
Funds raised during employee giving campaign (millions) $6.5 $7.90 $11.80 $13.0
Number of disaster relief efforts supported 7 9 10 14
Total amount donated to disaster relief organizations $0.4 $4.5 $2.6 $1.5
(excluding product donations, millions)
Looking ahead
As we enter a new decade, we are both inspired by the immunology and oncology are forthcoming. Over the coming
possibilities of new medical breakthroughs and aware of the years, we also expect the early-stage pipeline that we’ve been
challenges that lie ahead. building to mature. We are confident that new proof-of-concept
successes will emerge, bringing with them renewed promise for
The COVID-19 pandemic has transformed the world as we know
better treatments for conditions that have for too long diminished
it and we will continue to feel the impact for years to come. While
patients’ quality of life. We aim to elevate the standard of care,
we are proud of our efforts to date, we know we will need to be
with patients at the heart of everything we do.
agile in our continued response to evolving needs.
As we welcome Allergan, we will gain new colleagues, serve
In addition, the global public debate on the cost and delivery of
new patients and health care providers and operate in new
health care and the climate crisis continue to inspire and motivate
communities. We are excited to combine our passion and
us to find innovative approaches. Most importantly, these global
responsibility to transform patients’ lives globally for years
challenges highlight our role in addressing the needs of patients
to come.
and communities, here, now and in the future.
On the horizon in 2020, a number of late-stage data readouts
and regulatory submissions for additional indications in
Stay up to date on recent news, stories Polices, Codes and Compliance Standards
and more by connecting with us. Our public positions and views align with our work to improve
lives—and to do so in a transparent and sustainable way.
Additional policies, codes and compliance standards on a
range of areas are also publicly available.
Data assurance and reporting standards

Specified 2019 environmental and safety data have been
Stories.AbbVie.com assured by DNV GL. Where noted, minor changes have
been made to previously stated data.
AbbVie.com/responsibility
Responsibility@abbvie.com Our Environmental Assurance Report outlines performance

for corporate-wide environmental and safety data. All
Email us to subscribe to our quarterly environmental data is presented as absolute data; safety
responsibility e-newsletter. data is presented as rates, using hours worked.
For more information, visit:
abbvie.com
abbvie.com/responsibility
AbbVie Inc.
1 North Waukegan Road
North Chicago, IL 60064 U.S.A.
abbvie.com
©2020 AbbVie. All rights reserved.
Printed on recycled paper

Abbvie Sustainability

Uploaded by

Copyright:

Available Formats

Abbvie Sustainability

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Abbvie Sustainability

Uploaded by

Copyright:

Available Formats

2019

A message from our CEO . . . . . . . . . . . . . . . . . . . . . . . . . . 1

Our company and our business. . . . . . . . . . . . . . . . . . . . . 2

Our approach to corporate responsibility. . . . . . . . . . . . 4

Making a remarkable impact for patients. . . . . . . . . . . . 7

Building and supporting a diverse, . . . . . . . . . . . . . . . . . 19

Making positive contributions to society. . . . . . . . . . . . 27

The purpose of this report is to describe our approach to corporate

As we launched new treatments in immunology and oncology and continued to advance

It is my pleasure to introduce the AbbVie 2019 Responsible Action Report. It is intended

Our company and our business 2019

Equality, diversity and inclusion

Employee volunteerism and community engagement

We are proud of recognition received and use it to benchmark our efforts.

Our approach to corporate

Our corporate responsibility framework

We strive to make a remarkable impact on patients and drive sustainable

Driving innovation Acting with integrity Serving the community

Principles Transforming lives

Key issues We conduct research to make We advance patient, family and

We promote a diverse, inclusive

We support communities through

Our contributions to the Sustainable Development Goals

SDG Relevant Sub-Targets AbbVie’s Role

Making a remarkable impact

Commitment: Use our expertise to improve health

We invest in research to make innovative medicines

$5B in R&D our antibody-drug conjugates, most notably Rova-T and

Health outcomes research collaborations advancing patient care

Key performance indicators

Investment and Innovation 2016 2017 2018 2019

Research and development investment (adjusted) $4.15B $4.83B $5.09B $4.98B

New product or indication approvals including indication expansions 9 7 9 9

Number of programs granted a designation by at least one major regulatory 5 9 5 4

Commitment: Steward our ethical and sustainable business

We maintain high standards of ethics, safety

Ethics The Global Animal Welfare and Comparative Medicine

Safety We continued to advance the knowledge, skills and

Key performance indicators

Ethics, Compliance, Safety and Quality 2016 2017 2018 2019

Number of regulatory inspections of AbbVie commercial manufacturing facilities 41 52 37 27

Backorders as percentage of total orders <0.01% <0.01% <0.01% <0.01%

* This figure fluctuates with the workforce.

Commitment: Support long-term community strength

We advance patient, family and caregiver well-being

Bolstering Partners to Support Sick Children and Their Families

“AbbVie’s unwavering support has

“Even in the most difficult moments …

Building and supporting a diverse,

Commitment: Use our expertise to improve health

We promote a diverse, inclusive workplace and

Employee Resource Groups (ERGs)

“At AbbVie we strive to create an

ED&I Strategic Pillars

Key performance indicators

In 2019, we focused on attracting and sourcing talent by

Key performance indicators

Talent Attraction, Retention & Development 2016 2017 2018 2019

Overall turnover rate 9.2% 8.4% 8.6% 11.1%

“AbbVie’s unwavering support has

“Even in the most difficult moments …

“At AbbVie we strive to create an

“No one should feel like they can’t

The University of Chicago Education Lab: Through an “The only thing